mimmunМедицинская иммунологияMedical Immunology (Russia)1563-06252313-741XSPb RAACI10.15789/1563-0625-2013-1-5-12mimmun-24Research ArticleОБЗОРЫREVIEWSИММУНОРЕГУЛЯТОРНЫЕ ЭФФЕКТЫ ИММУНОГЛОБУЛИНОВ ДЛЯ ВНУТРИВЕННОГО ВВЕДЕНИЯIMMUNOREGULATORY EFFECTS OF INTRAVENOUS IMMUNOGLOBULINSСельковС. А.Sel'kovS. A.chepanovsv@gmail.comСоколовД. И.SokolovD. I.chepanovsv@gmail.comЧепановС. В.ChepanovS. V.

врач клинической лабораторной диагностики, лаборатория иммунологии

 

199034, Санкт-Петербург, Менделеевская линия, 3.

Тел.: (812) 328-98-50.

chepanovsv@gmail.comФедеральное государственное бюджетное учреждение «Научно-исследовательский институт акушерства и гинекологии им. Д.О. Отта» Северо-Западного отделения РАМН, Санкт-ПетербургRussian Federation201307072014151512Copyright © Сельков С.А., Соколов Д.И., Чепанов С.В., 20142014Сельков С.А., Соколов Д.И., Чепанов С.В.Sel'kov S.A., Sokolov D.I., Chepanov S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.mimmun.ru/mimmun/article/view/24

В современной медицинской практике широкое распространение получило использование препаратов внутривенных иммуноглобулинов в терапии различных патологических состояний, в том числе в акушерской клинике. К настоящему времени они стали препаратами выбора при лечении антифосфолипидного синдрома у беременных женщин, а также внутриутробной цитомегаловирусной инфекции

Treatment with intravenous immunoglobulins (IVIG) is widely used in modern clinical practice inorder to cure different clinical disorders, including obstetric conditions. Currently, IVIGs have become drugs of  choice  for  treatment of  anti-phospholipid  syndrome  in pregnant women,  like  as  in  cases of  intrauterine cytomegalovirus infection.

иммуноглобулины для внутривенного введенияантифосфолипидный синдромбеременностьintravenous immunoglobulinsantiphospholipid syndromepregnancyReferencesАверченков В.М., Плагин И.С. Внутривенные иммуноглобулины: механизмы действия и возможности клинического применения // Клиническая микробиология антимикробная химиотерапия. – 2004. – № 3.Аверченков В.М., Плагин И.С. Внутривенные иммуноглобулины: механизмы действия и возможности клинического применения // Клиническая микробиология антимикробная химиотерапия. – 2004. – № 3.Веденеева Г.Н., Фоменко Б.А., Евсюкова И.И., Сельков С.А. Состояние и последующее развитие новорожденных детей от матерей с цитомегаловирусной инфекцией // Рос. вестник перинатологии и педиатрии. – 1997. – Т. 42, № 3. – С. 25-29.Веденеева Г.Н., Фоменко Б.А., Евсюкова И.И., Сельков С.А. Состояние и последующее развитие новорожденных детей от матерей с цитомегаловирусной инфекцией // Рос. вестник перинатологии и педиатрии. – 1997. – Т. 42, № 3. – С. 25-29.Долгов В.В, Свирин П.В. Лабораторная диагностика нарушений гемостаза: учебное пособие. – М., 2005. – 195с.Долгов В.В, Свирин П.В. Лабораторная диагностика нарушений гемостаза: учебное пособие. – М., 2005. – 195с.Кондратенко И.В., Заплатников А.Л., Бологов А.А. Внутривенные иммуноглобулины: что и когда? // Детская больница. – 2010. – № 4.Кондратенко И.В., Заплатников А.Л., Бологов А.А. Внутривенные иммуноглобулины: что и когда? // Детская больница. – 2010. – № 4.Макацария А.Д., Бицадзе В.О. Антифосфолипидный синдром, генетические тромбофилии в патогенезе основных форм акушерской патологии // Русский медицинский журнал. – 2006. – Специальный выпуск. – С. 2-10.Макацария А.Д., Бицадзе В.О. Антифосфолипидный синдром, генетические тромбофилии в патогенезе основных форм акушерской патологии // Русский медицинский журнал. – 2006. – Специальный выпуск. – С. 2-10.Мигунов В.Н., Ковалева Л.Г. Иммуноглобулины и их применение в клинической практике. Общая характеристика // www.blood.ru 30.01.06 г.Мигунов В.Н., Ковалева Л.Г. Иммуноглобулины и их применение в клинической практике. Общая характеристика // www.blood.ru 30.01.06 г.Насонов Е.Л. Антифосфолипидный синдром. – М.: Литтерра, 2004. – 440 с.Насонов Е.Л. Антифосфолипидный синдром. – М.: Литтерра, 2004. – 440 с.Румянцев А.Г. Основные свойства внутривенных иммуноглобулинов и показания к их применению // Вопросы онкологии, гематологии и иммунопатологии в педиатрии. – 2011. – Т. 10, № 2. – С. 39-50.Румянцев А.Г. Основные свойства внутривенных иммуноглобулинов и показания к их применению // Вопросы онкологии, гематологии и иммунопатологии в педиатрии. – 2011. – Т. 10, № 2. – С. 39-50.Сельков С.А., Селютин А.В., Зайнулина М.С. Влияние иммуномодулирующей терапии на клинико-лабораторные показатели беременных с невынашиванием и антифосфолипидным синдромом // Журнал акушерства и женских болезней. – 2011. – № 3. – С. 152-160.Сельков С.А., Селютин А.В., Зайнулина М.С. Влияние иммуномодулирующей терапии на клинико-лабораторные показатели беременных с невынашиванием и антифосфолипидным синдромом // Журнал акушерства и женских болезней. – 2011. – № 3. – С. 152-160.Сидельникова В.М. «Привычная потеря беременности»: руководство. – М.: Триада-Х, 2000. – 304 с.Сидельникова В.М. «Привычная потеря беременности»: руководство. – М.: Триада-Х, 2000. – 304 с.Ушкалова Е.А., Шифман Е.М. Проблема нерегламентированного применения иммуноглобулина для внутривенного введения в акушерстве // Акушерство и гинекология. – 2011. – № 3. – С. 74-80Ушкалова Е.А., Шифман Е.М. Проблема нерегламентированного применения иммуноглобулина для внутривенного введения в акушерстве // Акушерство и гинекология. – 2011. – № 3. – С. 74-80Ярилин А.А. Иммунология: учебник. – М.: ГЭОТАР-Медиа, 2010. – 752 с.Ярилин А.А. Иммунология: учебник. – М.: ГЭОТАР-Медиа, 2010. – 752 с.Krupa A., Fudala R., Stankowska D. Anti-Chemokine Autoantibody: Chemokine Immune Complexes Activate Endothelial Cells via IgG Receptors // Am. J. Respir Cell Mol. Biol. – 2009. – Aug; 41 (2). – P. 155-169.Krupa A., Fudala R., Stankowska D. Anti-Chemokine Autoantibody: Chemokine Immune Complexes Activate Endothelial Cells via IgG Receptors // Am. J. Respir Cell Mol. Biol. – 2009. – Aug; 41 (2). – P. 155-169.Kessel А., Ammuri H., Peri R. Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function // The J. of Immunology. – 2007. – Oct. 15; 179 (8). – P. 5571-5575Kessel А., Ammuri H., Peri R. Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function // The J. of Immunology. – 2007. – Oct. 15; 179 (8). – P. 5571-5575Arnout J., Jankowski M. Antiphospholipid syndrome // The Hematology J. – 2004. – N 5. – P. 1-5.Arnout J., Jankowski M. Antiphospholipid syndrome // The Hematology J. – 2004. – N 5. – P. 1-5.Blanchette V.S., Luke B., Andrew M. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura // J. Pediatr. – 1993. – Dec; 123 (6). – P. 989-95.Blanchette V.S., Luke B., Andrew M. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura // J. Pediatr. – 1993. – Dec; 123 (6). – P. 989-95.Chen Zhiqi. Cloning and characterization of the human CD200 promoter region // A thesis submitted in conformity with the requirements for the degree of Master of Science, Graduate Department of the Institute of Medical Science. – University of Toronto, 2001. – P. 85.Chen Zhiqi. Cloning and characterization of the human CD200 promoter region // A thesis submitted in conformity with the requirements for the degree of Master of Science, Graduate Department of the Institute of Medical Science. – University of Toronto, 2001. – P. 85.Chong B.H., Chong J.J. IVIg immune inhibitory activity: APC is key // Blood. – 2010. Mar 4; 115 (9). – P. 1663-64.Chong B.H., Chong J.J. IVIg immune inhibitory activity: APC is key // Blood. – 2010. Mar 4; 115 (9). – P. 1663-64.Core SPC for human normal immunoglobulin for intravenous administration (IVIg) // European Medicines Agency Evaluation of Medicines for Human Use. London 2004. – July. – CPMP/ BPWG/859/95 rev. 2.Core SPC for human normal immunoglobulin for intravenous administration (IVIg) // European Medicines Agency Evaluation of Medicines for Human Use. London 2004. – July. – CPMP/ BPWG/859/95 rev. 2.Criteria for the clinical use of intravenous immunoglobulin in Australia // Second Edition 2012.Criteria for the clinical use of intravenous immunoglobulin in Australia // Second Edition 2012.Clark D.A., Wong K., Banwatt D. CD200-dependent and nonCD200-dependant pathways of NK cell suppression by human IVIG // J. Assist. Reprod. Genet. – 2008. – March; 25(2-3). – P. 67-72.Clark D.A., Wong K., Banwatt D. CD200-dependent and nonCD200-dependant pathways of NK cell suppression by human IVIG // J. Assist. Reprod. Genet. – 2008. – March; 25(2-3). – P. 67-72.Empson M.B, Lassere M. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant (Review) // The Cochrane Library 2011. – Issue 3.Empson M.B, Lassere M. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant (Review) // The Cochrane Library 2011. – Issue 3.Nimmerjahn F., Ravetch J.V. Fcγ receptors as regulators of immune responses // Nature Reviews mmunology. – 2007. – Vol. 8. – P. 34-47.Nimmerjahn F., Ravetch J.V. Fcγ receptors as regulators of immune responses // Nature Reviews mmunology. – 2007. – Vol. 8. – P. 34-47.Fishman P., Bar-Yehuda S., Shoenfeld Y. IVIg to prevent tumor metastases // Int. J. Oncol. – 2002. – Oct; 21 (4). – P. 875-880.Fishman P., Bar-Yehuda S., Shoenfeld Y. IVIg to prevent tumor metastases // Int. J. Oncol. – 2002. – Oct; 21 (4). – P. 875-880.Freiberger T., Grodecká L. Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency // Clin Immunol. – 2010. – Sep; 136 (3). – P. 419-425.Freiberger T., Grodecká L. Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency // Clin Immunol. – 2010. – Sep; 136 (3). – P. 419-425.Jacob H. Rand. Molecular Pathogenesis of the Antiphospholipid Syndrome // Circulation Research. – 2002. – January. – P. 29-37.Jacob H. Rand. Molecular Pathogenesis of the Antiphospholipid Syndrome // Circulation Research. – 2002. – January. – P. 29-37.Jean-Eric Alard, Fanny Gaillard, Capucine Daridon. TLR2 Is One of the Endothelial Receptors for β2-Glycoprotein I // J. Immunol. – 2010. – Aug 1; 185 (3). – P. 1550-1557Jean-Eric Alard, Fanny Gaillard, Capucine Daridon. TLR2 Is One of the Endothelial Receptors for β2-Glycoprotein I // J. Immunol. – 2010. – Aug 1; 185 (3). – P. 1550-1557Bayry J., Lacroix-Desmazes S., Carbonneil C. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin // Blood. – 2003. – Jan 15; 101 (2). – P. 758-765.Bayry J., Lacroix-Desmazes S., Carbonneil C. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin // Blood. – 2003. – Jan 15; 101 (2). – P. 758-765.Harris E.N., Charavi A.E. Anti-cardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus // Ibid. – 1983. – Vol. 2. – P. 1211-1214.Harris E.N., Charavi A.E. Anti-cardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus // Ibid. – 1983. – Vol. 2. – P. 1211-1214.Hughes G.R.V. Thrombosis, abortion, cerebral disease and lupus anticoagulant // Brit. Med. J. – 1983. – Vol. 187. – P. 1088-1089.Hughes G.R.V. Thrombosis, abortion, cerebral disease and lupus anticoagulant // Brit. Med. J. – 1983. – Vol. 187. – P. 1088-1089.Human normal immunoglobulin for intravenous administration // European Pharmacopoeia PA/PH/Exp. 6B/T (11) 14 PUB.Human normal immunoglobulin for intravenous administration // European Pharmacopoeia PA/PH/Exp. 6B/T (11) 14 PUB.Tanigaki K., Mineo Ch., Ivan S. C-Reactive Protein Inhibits Insulin Activation of Endothelial Nitric Oxide Synthase via the Immunoreceptor Tyrosine-Based Inhibition Motif of FcγRIIB and SHIP-1 // Circ. Res. – 2009. – June 5; 104 (11). – P. 1275-1282.Tanigaki K., Mineo Ch., Ivan S. C-Reactive Protein Inhibits Insulin Activation of Endothelial Nitric Oxide Synthase via the Immunoreceptor Tyrosine-Based Inhibition Motif of FcγRIIB and SHIP-1 // Circ. Res. – 2009. – June 5; 104 (11). – P. 1275-1282.Damianovich M., Blank M., Raiter A. Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg) // International Immunology. – 2009. – Vol. 21, N 9. – P. 1057-1063.Damianovich M., Blank M., Raiter A. Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg) // International Immunology. – 2009. – Vol. 21, N 9. – P. 1057-1063.Meroni P.L., Borghi M.O. Pathogenesis of antiphospholipid syndrome: understanding the antibodies // Nat. Rev. Rheumatol. – 2011. – Jun; 7 (6). – P. 330-39.Meroni P.L., Borghi M.O. Pathogenesis of antiphospholipid syndrome: understanding the antibodies // Nat. Rev. Rheumatol. – 2011. – Jun; 7 (6). – P. 330-39.Miletic VD, Hester CG and Frank MM. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes // The J. of Immunology. – 1996. – Vol. 156, Issue 2. – P. 749-757.Miletic VD, Hester CG and Frank MM. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes // The J. of Immunology. – 1996. – Vol. 156, Issue 2. – P. 749-757.Goebl N.A., Babbey C.M. Neonatal Fc Receptor Mediates Internalization of Fc in Transfected Human Endothelial Cells // Mol. Biol. Cell. – 2008. – December; 19 (12). – P. 5490-5505.Goebl N.A., Babbey C.M. Neonatal Fc Receptor Mediates Internalization of Fc in Transfected Human Endothelial Cells // Mol. Biol. Cell. – 2008. – December; 19 (12). – P. 5490-5505.Dussault N., Ducas E., Racine C. Immunomodulation of human B cells following treatment with intravenous immunoglobulins involves increased phosphorylation of extracellular signal-regulated kinases 1 and 2 // International Immunology. – 2008. – Vol. 20, N 11. – P. 1369-1379.Dussault N., Ducas E., Racine C. Immunomodulation of human B cells following treatment with intravenous immunoglobulins involves increased phosphorylation of extracellular signal-regulated kinases 1 and 2 // International Immunology. – 2008. – Vol. 20, N 11. – P. 1369-1379.Barclay N., Gavin J. CD200 and membrane protein interactions in the control of myeloid cells // Trends in Immunology. – 2002. – Vol. 23, Issue 6, 1 June. – P. 285-290.Barclay N., Gavin J. CD200 and membrane protein interactions in the control of myeloid cells // Trends in Immunology. – 2002. – Vol. 23, Issue 6, 1 June. – P. 285-290.Nigro G., Adler S.P., La Torre R., Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. // N. Engl. J. Med. – 2005. – N 353. – P. 1350-62.Nigro G., Adler S.P., La Torre R., Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. // N. Engl. J. Med. – 2005. – N 353. – P. 1350-62.Nimmerjahn F., Ravetch J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox // J. Exp Med. – 2007. – Jan 22; 204 (1). – P. 11-15.Nimmerjahn F., Ravetch J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox // J. Exp Med. – 2007. – Jan 22; 204 (1). – P. 11-15.Nimmerjahn F., Ravetch J.V. Fcg Receptors: Old Friends Review and New Family Members // Immunity. – 2006. – Jan 24. – P. 19-28.Nimmerjahn F., Ravetch J.V. Fcg Receptors: Old Friends Review and New Family Members // Immunity. – 2006. – Jan 24. – P. 19-28.Oates-Whitehead R.M., Baumer J.H., Haines L., Love S. Intravenous immunoglobulin for the treatment of Kawasaki disease in children // Cochrane Database Syst. Rev. – 2003; (4): CD004000.Oates-Whitehead R.M., Baumer J.H., Haines L., Love S. Intravenous immunoglobulin for the treatment of Kawasaki disease in children // Cochrane Database Syst. Rev. – 2003; (4): CD004000.Travers P., Walport M., Shlomchik M. Immunobiology: By Charles Janeway. – 2004. – 6th EditionTravers P., Walport M., Shlomchik M. Immunobiology: By Charles Janeway. – 2004. – 6th EditionPorter T.F., La Coursiere Y., Scott J.R. Immunotherapy for recurrent miscarriage: review The Cochrane Collaboration. – 2010.Porter T.F., La Coursiere Y., Scott J.R. Immunotherapy for recurrent miscarriage: review The Cochrane Collaboration. – 2010.Radulescu L., Antohe F. Neonatal Fc receptors discriminates and monitors the pathway of native and modified immunoglobulin G in placental endothelial cells // Hum. Immunol. – 2004 . – June; 65 (6). – P. 578-585.Radulescu L., Antohe F. Neonatal Fc receptors discriminates and monitors the pathway of native and modified immunoglobulin G in placental endothelial cells // Hum. Immunol. – 2004 . – June; 65 (6). – P. 578-585.Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor // Science. – 2001. – Jan 19; 291 (5503). – P. 484-486.Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor // Science. – 2001. – Jan 19; 291 (5503). – P. 484-486.Sewell W.A.C., Jolles S. Immunomodulatory action of intravenous immunoglobulin // Immunology. – 2002. – December; 107 (4). – P. 387- 393.Sewell W.A.C., Jolles S. Immunomodulatory action of intravenous immunoglobulin // Immunology. – 2002. – December; 107 (4). – P. 387- 393.Sewell W.A.C., North M.E., Cambronero R. In vivo modulation of cytokine synthesis by intravenous immunoglobulin // Clin. Exp. Immunol. – 1999. – June; 116 (3). – P. 509-515.Sewell W.A.C., North M.E., Cambronero R. In vivo modulation of cytokine synthesis by intravenous immunoglobulin // Clin. Exp. Immunol. – 1999. – June; 116 (3). – P. 509-515.Vielma S., Virella G., Gorod A.J. Chlamydophila pneumoniae Infection of Human Aortic Endothelial Cells Induces the Expression of FC-Receptor II (Fc_RII) // Clinical Immunology. – 2002. – Vol. 104, N 3, September. – P. 265-273.Vielma S., Virella G., Gorod A.J. Chlamydophila pneumoniae Infection of Human Aortic Endothelial Cells Induces the Expression of FC-Receptor II (Fc_RII) // Clinical Immunology. – 2002. – Vol. 104, N 3, September. – P. 265-273.Devaraj S., Davis B., Simon S.I. CRP promotes monocyte-endothelial cell adhesion via Fc_ receptors in human aortic endothelial cells under static and hear flow conditions // Am. J. Physiol. Heart Circ. Physiol. – 2006. – Sep; 291 (3). – P. 1170-1176.Devaraj S., Davis B., Simon S.I. CRP promotes monocyte-endothelial cell adhesion via Fc_ receptors in human aortic endothelial cells under static and hear flow conditions // Am. J. Physiol. Heart Circ. Physiol. – 2006. – Sep; 291 (3). – P. 1170-1176.Stephenson M.D., Kutteh W.H. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial // Human Reproduction. – 2010. – Vol. 25, N 9. – P. 2203-2209Stephenson M.D., Kutteh W.H. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial // Human Reproduction. – 2010. – Vol. 25, N 9. – P. 2203-2209Tha-In T., Metselaar H.J. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells // Blood. – 2007. –Vol. 110, N 9. – P. 3253-62.Tha-In T., Metselaar H.J. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells // Blood. – 2007. –Vol. 110, N 9. – P. 3253-62.Arumugam T.V., Tang S.-C. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death // PNAS. – 2007. – Vol. 104, N 35. – P. 14104-14109.Arumugam T.V., Tang S.-C. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death // PNAS. – 2007. – Vol. 104, N 35. – P. 14104-14109.Tripodi A., de Groot P.G., Pengo V. Antiphospholipid syndrome: laboratory detection, mechanism of action and treatment // J. of Internal Medicine. – 2011. – Aug 270 (2). – P. 110-22.Tripodi A., de Groot P.G., Pengo V. Antiphospholipid syndrome: laboratory detection, mechanism of action and treatment // J. of Internal Medicine. – 2011. – Aug 270 (2). – P. 110-22.Urbanus R.T., de Groot P.G. Antiphospholipid antibodies--we are not quite there yet // Blood Rev. – 2011. – Mar; 25 (2). – P. 97-106.Urbanus R.T., de Groot P.G. Antiphospholipid antibodies--we are not quite there yet // Blood Rev. – 2011. – Mar; 25 (2). – P. 97-106.Gill V., Doig Ch., Knight D. Targeting Adhesion Molecules as a Potential Mechanism of Action for Intravenous Immunoglobulin // Vascular Medicine. – 2005. – 112 (13). – P. 2031-2039.Gill V., Doig Ch., Knight D. Targeting Adhesion Molecules as a Potential Mechanism of Action for Intravenous Immunoglobulin // Vascular Medicine. – 2005. – 112 (13). – P. 2031-2039.Wim K., Jessica L., Teeling C. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect // Blood. – 2001. – Vol. 98, N 10. – P. 3136-3142.Wim K., Jessica L., Teeling C. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect // Blood. – 2001. – Vol. 98, N 10. – P. 3136-3142.Wong R.C., Favaloro E.J. Clinical features, diagnosis, and management of the antiphospholipid syndrome // Thromb Hemost. – 2008. – Apr; 34 (3). – P. 295-304.Wong R.C., Favaloro E.J. Clinical features, diagnosis, and management of the antiphospholipid syndrome // Thromb Hemost. – 2008. – Apr; 34 (3). – P. 295-304.Wright G.J., Cherwinski H., Foster-Cuevas M. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200 // J. Immunol. – 2003. – Sep 15; 171 (6) – P. 3034-46.Wright G.J., Cherwinski H., Foster-Cuevas M. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200 // J. Immunol. – 2003. – Sep 15; 171 (6) – P. 3034-46.Xu C, Poirier B. Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases // Am. J. Pathol. – 1998. – Oct; 153 (4). – P. 1257-66.Xu C, Poirier B. Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases // Am. J. Pathol. – 1998. – Oct; 153 (4). – P. 1257-66.Shoenfeld Y., Levy Y., Fishman P. Shrinkage of Melanoma Metastases Following High Dose Intravenous Immunoglobulin Treatment // IMAJ. – 2001. – Vol. 3. – P. 698-699.Shoenfeld Y., Levy Y., Fishman P. Shrinkage of Melanoma Metastases Following High Dose Intravenous Immunoglobulin Treatment // IMAJ. – 2001. – Vol. 3. – P. 698-699.

The authors declare that there are no conflicts of interest present.